Klinische studies acute myeloïde leukemie (AML)

Onbehandelde patiënten

cAMeLot-2 (75276617AML3001)

A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT06852222
• Internal reference number: S70109

QuANTUM-Wild (AC220-168)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD (-) Acute Myeloid Leukemia (QuANTUM-Wild)

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT06578247
• Internal reference number: S69793

HOVON 177 (EVOLVE-2)

Randomized study assessing azacitidine and venetoclax with or without revumenib in adult patients with newly diagnosed NPM1 mutated or KMT2A rearranged AML ineligible for intensive chemotherapy

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT06652438
• Internal reference number: S70299

Hovon 173 (EVOLVE-1)

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT07075016
• Internal reference number: S70027

Behandelde patiënten

DSP-5336-101

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL)-rearrangement or Nucleophosmin 1 (NPM1) Mutation

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT04988555
• Internal reference number: S67836